IDXX — IDEXX LABORATORIES INC /DE
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 874716 ·
Last close
$690.24
Market Cap
$54.38B
52W High
$769.98
52W Low
$500.61
ADV30
651,209
Next earnings
2027-02-01
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 1,216,585,000 | 779,087,000 | 425,566,000 | 338,412,000 | 3,442,335,000 | 196,933,000 | 1,829,760,000 |
| Mar 2026 | 1,140,820,000 | 722,739,000 | 362,586,000 | 278,446,000 | 3,385,497,000 | 200,528,000 | 1,829,394,000 |
| Dec 2025 | 1,090,579,000 | 658,114,000 | 315,605,000 | 248,188,000 | 3,350,759,000 | 180,070,000 | 1,745,376,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,418,887,000
Investing CF
$-335,270,000
Financing CF
$-1,093,168,000
CapEx
$-118,886,000
Dividends Paid
—
Buybacks
$-1,047,788,000
EPS Diluted TTM
$14.83
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$7,325,905,000
Inventory
$390,874,000
Receivables
$721,318,000
ST Investments
—
EBIT TTM
$1,513,565,000
Pretax Income TTM
$1,478,973,000
Interest Exp TTM
$34,592,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,662,220,800
EBITDA
$1,673,122,944
Free Cash Flow
$1,064,129,600
Enterprise Value
$54,038,093,824
Total Cash
$197,536,000
Total Debt
$972,963,008
Shares Out
78,786,265
Trailing EPS
$14.84
Book Value
$23.72
ROE
68.9%
ROA
26.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,303,702,000 | 1,360,031,000 | 1,059,464,000 | 3,350,759,000 | 1,745,376,000 | 1,605,383,000 | 1,181,805,000 |
| Dec 2024 | 3,897,504,000 | 1,128,337,000 | 887,867,000 | 3,293,443,000 | 1,698,130,000 | 1,595,313,000 | 929,001,000 |
| Dec 2023 | 3,660,953,000 | 1,097,128,000 | 845,042,000 | 3,259,925,000 | 1,775,395,000 | 1,484,530,000 | 906,510,000 |
| Dec 2022 | 3,367,324,000 | 898,765,000 | 679,089,000 | 2,746,765,000 | 2,138,028,000 | 608,737,000 | 542,984,000 |
TTM Snapshot
Revenues TTM
$4,553,223,000
NetIncome TTM
$1,139,656,000
OpCashFlow TTM
—
Assets (Latest)
$3,442,335,000
Forward EPS
$16.88
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $600.00 · spot: $698.47 · call volume: 80 · put volume: 420
Expected Move to 2026-12-18:
±$58.40
(8.36%) —
implied range
$640.07 –
$756.87
· ATM straddle on $700.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IQV | IQVIA HOLDINGS INC. | $42.45B | $257.60 | — |
| INCY | INCYTE CORP | $24.27B | $119.09 | — |
| MEDP | Medpace Holdings, Inc. | $18.27B | $653.09 | — |
| CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | $15.92B | $332.16 | — |
| ICLR | ICON PLC | $15.05B | $195.02 | — |
News headlines (Yahoo Finance, 1h cache)
3 Stocks Rallying After Strong Q3 Earnings and Raised Guidance
2026-11-17 19:13 · Yahoo
How IDEXX Stock Is Engineered To Make Money For You
2026-11-07 01:10 · Yahoo
3 Reasons Growth Investors Will Love Idexx (IDXX)
2026-11-06 16:45 · Yahoo
IDEXX Laboratories (IDXX) Q3 Earnings Leave Its Premium Valuation In Focus
2026-11-03 23:22 · Yahoo
Idexx Laboratories (IDXX) Crossed Above the 200-Day Moving Average: What That Means for Investors
2026-11-03 13:30 · Yahoo
Company News for Nov 3, 2026
2026-11-03 13:22 · Yahoo
Top Stock Reports for Merck, Caterpillar & Union Pacific
2026-11-18 20:27 · Yahoo
Should You Continue to Hold Charles River Stock in Your Portfolio?
2026-11-18 13:47 · Yahoo
Should You Continue to Hold Medtronic Stock in Your Portfolio?
2026-11-18 12:22 · Yahoo
Invesco S&P 500 Equal Weight (RSP) Buys $0.7 Million More PTC on Nov. 16
2026-11-18 11:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.